Next Article in Journal
An Advanced Bioreactor Simulating Dynamic Physiological Conditions in the Human Ascending Colon: MimiCol3
Previous Article in Journal
Phytopigment Alizarin Inhibits Multispecies Biofilm Development by Cutibacterium acnes, Staphylococcus aureus, and Candida albicans
Previous Article in Special Issue
Nanocarriers Based on Gold Nanoparticles for Epigallocatechin Gallate Delivery in Cancer Cells
Review

Efficacy of Polymer-Based Nanomedicine for the Treatment of Brain Cancer

Department of Chemistry, University of Fort Hare, Alice Campus, Eastern Cape 5700, South Africa
*
Author to whom correspondence should be addressed.
Academic Editors: Manuel A.N. Coelho and Sílvia Castro Coelho
Pharmaceutics 2022, 14(5), 1048; https://doi.org/10.3390/pharmaceutics14051048
Received: 28 February 2022 / Revised: 18 March 2022 / Accepted: 23 March 2022 / Published: 13 May 2022
(This article belongs to the Special Issue Nanocarriers for Cancer Therapy and Diagnosis)
Malignant brain tumor is a life-threatening disease with a low survival rate. The therapies available for the treatment of brain tumor is limited by poor uptake via the blood–brain barrier. The challenges with the chemotherapeutics used for the treatment of brain tumors are poor distribution, drug toxicity, and their inability to pass via the blood–brain barrier, etc. Several researchers have investigated the potential of nanomedicines for the treatment of brain cancer. Nanomedicines are designed with nanosize particle sizes with a large surface area and are loaded with bioactive agents via encapsulation, immersion, conjugation, etc. Some nanomedicines have been approved for clinical use. The most crucial part of nanomedicine is that they promote drug delivery across the blood–brain barrier, display excellent specificity, reduce drug toxicity, enhance drug bioavailability, and promote targeted drug release mechanisms. The aforementioned features make them promising therapeutics for brain targeting. This review reports the in vitro and in vivo results of nanomedicines designed for the treatment of brain cancers. View Full-Text
Keywords: nanomedicine; drug delivery; brain cancer; tumor; blood–brain barrier; anticancer drugs nanomedicine; drug delivery; brain cancer; tumor; blood–brain barrier; anticancer drugs
Show Figures

Figure 1

MDPI and ACS Style

Naki, T.; Aderibigbe, B.A. Efficacy of Polymer-Based Nanomedicine for the Treatment of Brain Cancer. Pharmaceutics 2022, 14, 1048. https://doi.org/10.3390/pharmaceutics14051048

AMA Style

Naki T, Aderibigbe BA. Efficacy of Polymer-Based Nanomedicine for the Treatment of Brain Cancer. Pharmaceutics. 2022; 14(5):1048. https://doi.org/10.3390/pharmaceutics14051048

Chicago/Turabian Style

Naki, Tobeka, and Blessing A. Aderibigbe. 2022. "Efficacy of Polymer-Based Nanomedicine for the Treatment of Brain Cancer" Pharmaceutics 14, no. 5: 1048. https://doi.org/10.3390/pharmaceutics14051048

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop